Breaking News Instant updates and real-time market news.

PCG

PG&E

$23.10

0.3 (1.32%)

, WM

Waste Management

$104.14

2.35 (2.31%)

09:55
04/15/19
04/15
09:55
04/15/19
09:55

Early notable gainers among liquid option names on April 15th

Notable gainers among liquid option names this morning include PG&E (PCG) $24.04 +1.23, Waste Management (WM) $104.51 +2.72, CVS Health (CVS) $53.85 +1.05, Bristol Myers Squibb (BMY) $46.19 +0.61, and UnitedHealth (UNH) $226.05 +2.79.

PCG

PG&E

$23.10

0.3 (1.32%)

WM

Waste Management

$104.14

2.35 (2.31%)

CVS

CVS Health

$53.79

0.98 (1.86%)

BMY

Bristol-Myers

$45.91

0.33 (0.72%)

UNH

UnitedHealth

$226.08

2.91 (1.30%)

  • 15

    Apr

  • 16

    Apr

  • 17

    Apr

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 05

    May

  • 14

    May

  • 18

    May

  • 20

    May

  • 29

    May

  • 30

    May

PCG PG&E
$23.10

0.3 (1.32%)

04/15/19
SBSH
04/15/19
NO CHANGE
SBSH
Citi reiterates Buy ratings on PG&E, Edison after strike team report
Governor Newsom's press conference and the strike team report unveiled on Friday gives confidence that California will "get something constructive accomplished by July," Citi analyst Praful Mehta tells investors in a research note. The Governor highlighted that a solution requires participation from everybody including investors, insurers, attorneys and tax payers, adds the analyst. He finds this statement "extremely important" and reiterates Buy ratings on both PG&E (PFE) and Edison International (EIX).
02/26/19
ARGS
02/26/19
UPGRADE
ARGS
Hold
PG&E upgraded to Hold from Sell at Argus
02/19/19
02/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying McDonald's core U.S. business is accelerating and positioned to show upside to consensus estimates for Q1 and fiscal 2019. 2. PG&E (PCG) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying recent comments by California Governor Gavin Newsom indicate an "increasingly likelihood of legislative action." 3. PepsiCo (PEP) upgraded to Outperform from Neutral at Macquarie with analyst Caroline Levy saying new CEO Ramon Laguarta "moved decisively" to reset for sustained 4%-6% sales growth by stepping up marketing and capital spending. 4. Freeport McMoRan (FCX) upgraded to Buy from Neutral at Citi while Southern Copper (SCCO) was double upgraded to Buy from Sell. 5. Cosan (CZZ) upgraded to Overweight from Neutral at JPMorgan with analyst Lucas Ferreira saying the shares trade at an "excessive" 40% discount to net asset value, in the upper part of the 30%-40% range where the stock should be trading. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
SBSH
02/19/19
UPGRADE
Target $31
SBSH
Buy
PG&E upgraded to Buy from Neutral at Citi
Citi analyst Praful Mehta upgraded PG&E to Buy with a $31 price target. Recent comments by California Governor Gavin Newsom indicate an "increasingly likelihood of legislative action," Mehta tells investors in a research note. The analyst believes legislation could limit PG&E's future wildfire risk and unlock "significant upside" in the shares. While Mehta expects legislative action, he "conservatively" assumes "some liabilities" from 2019 fires. PG&E in premarket trading is up 8%, or $1.20, to $16.68.
WM Waste Management
$104.14

2.35 (2.31%)

04/15/19
STFL
04/15/19
UPGRADE
STFL
Buy
Stifel upgrades Waste Management, Advanced Disposal each to Buy after deal
As previously reported, Stifel analyst Michael Hoffman upgraded Waste Management (WM) to Buy from Hold and raised his price target on the stock to $115 from $103 and also upgraded Advanced Disposal Services (ADSW) to Buy from Hold and raised his target on its shares to $35 from $30 after the companies announced a deal to combine. Even with potential divestitures to get the deal approved, adding Advanced Disposal "dramatically lowers" Waste Management's cost of capital, reduces capital spending, converts more of the fleet to CNG, and stimulates tuck-in activity that should all drive sustainable free cash flow growth, contend Hoffman.
04/15/19
STFL
04/15/19
UPGRADE
STFL
Buy
Waste Management upgraded to Buy from Hold at Stifel
04/11/19
04/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chipotle (CMG) downgraded to Hold from Buy at Jefferies with analyst Andrew Barish saying after rallying 65% in Q1, Chipotle's valuation is full and reflects improved visibility for "powerful" same-store-sales and margin drivers. 2. Eli Lilly (LLY) downgraded to Neutral from Buy at Guggenheim with analyst Seamus Fernandez saying while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. 3. U.S. Steel (X) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners citing worse near-term U.S. market conditions than she anticipated. 4. Keurig Dr Pepper (KDP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying she sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. 5. Waste Management (WM) downgraded to Hold from Buy at Stifel with analyst Michael Hoffman saying he factors in incrementally weaker paper prices and the impact of wet weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
STFL
04/11/19
DOWNGRADE
Target $103
STFL
Hold
Waste Management downgraded to Hold from Buy at Stifel
Stifel analyst Michael Hoffman downgraded Waste Management (WM) to Hold from Buy as he factors in incrementally weaker paper prices and the impact of wet weather. Hoffman believes solid waste fundamentals are good, but his recycling assumptions are now worse, he tells investors. The analyst, who also downgraded Waste Connections (WCN), Advanced Disposal Services (ADSW) and Republic Services (RSG) to Hold this morning, keeps a $103 price target on Waste Management shares.
CVS CVS Health
$53.79

0.98 (1.86%)

04/15/19
OPCO
04/15/19
DOWNGRADE
OPCO
Perform
CVS Health downgraded to Perform from Outperform at Oppenheimer
04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
BMOC
04/10/19
INITIATION
BMOC
Market Perform
CVS Health initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated CVS Health with a Market Perform rating and a $58 price target. The analyst said that he is aware of the low valuation of the stock, but is "wary of further deterioration in the outlook given headwinds on CVS legacy businesses that have recently intensified," and is not confident "the pressures will diminish next year."
04/15/19
04/15/19
DOWNGRADE

Perform
CVS Health downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Michael Wiederhorn downgraded CVS Health to Perform from Outperform saying that he is looking to reset the bar on his rating, as he views it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges. Furthermore, the analyst expects the drug-price noise out of Washington to continue for the foreseeable future. Lastly, Wiederhorn notes that he remains bullish on the overall managed care sector, but CVS's exposure to the business is still quite modest, and he would prefer other names in the space right now.
BMY Bristol-Myers
$45.91

0.33 (0.72%)

04/02/19
BERN
04/02/19
DOWNGRADE
BERN
Market Perform
Celgene downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Aaron Gal downgraded Celgene (CELG) to Market Perform from Outperform as spread narrows. The analyst notes that the current controversy on Celgene is whether the Bristol-Myers (BMY) acquisition will close. With limited upside, no differentiated views on the main controversy, and ahead of the shareholder vote on April 12th, the analyst is moving to the sidelines.
04/01/19
WBLR
04/01/19
DOWNGRADE
WBLR
Market Perform
Celgene downgraded to Market Perform from Outperform at William Blair
William Blair analyst Andy Hsieh downgraded Celgene (CELG) to Market Perform from Outperform saying the recent proxy recommendations set the course for the takeover by Bristol-Myers Squibb (BMY) winning shareholder approval.
04/05/19
CANT
04/05/19
DOWNGRADE
Target $100
CANT
Neutral
Cantor sees Bristol deal closing, downgrades Celgene to Neutral
Cantor Fitzgerald analyst Alethia Young downgraded Celgene (CELG) to Neutral from Overweight with an unchanged price target of $100. The analyst expects the takeover by Bristol-Myers (BMY) to close.
04/01/19
UBSW
04/01/19
DOWNGRADE
Target $102
UBSW
Neutral
Celgene downgraded to Neutral from Buy at UBS
UBS analyst Carter Gould downgraded Celgene (CELG) to Neutral from Buy while raising his price target for the shares to $102 from $94. After ISS and Glass Lewis on Friday recommended that Bristol-Myers Squibb (BMY) shareholders vote in favor of the proposed acquisition, and Starboard dropped its proxy solicitation in opposition, the analyst sees an increasingly high probability that Bristol's acquisition of Celgene will be completed. He sees any lingering risks around antitrust concerns and Revlimid litigation as unlikely to derail the deal.
UNH UnitedHealth
$226.08

2.91 (1.30%)

03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Overweight
Myriad traded lower on 'minor' United Healthcare change, says Piper Jaffray
Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as "minor" and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
04/02/19
JEFF
04/02/19
UPGRADE
Target $107
JEFF
Buy
Quest, LabCorp upgraded to Buy ahead of UnitedHealth lab network rollout
Jefferies analyst Brian Tanquilut upgraded both Quest Diagnostics (DGX) and Laboratory Corp. of America (LH) to Buy from Hold on the belief that UnitedHealth's (UNH) rollout on July 1 of its preferred lab network will be a positive catalyst for both stocks. Quest and LabCorp's likely inclusion should bolster their organic growth beginning in 2020, Tanquilut tells investors in a research note. The analyst finds both stocks "compelling" with their 2019 outlooks "seemingly de-risked with fairly conservative guidance ranges" and 2020 consensus estimates "looking conservative." Further, Quest's and LabCorp's valuations are at below-historical relative averages, Tanquilut contends. The analyst raised his price target for Laboratory Corp. to $190 from $154 and for Quest to $107 from $93.
04/10/19
CANT
04/10/19
NO CHANGE
CANT
Senate hearing a net positive for PBMs, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views yesterday's Senate hearing as a net positive for the pharmacy benefit managers. The PBMs represented were Cigna (CI), CVS Health (CVS), UnitedHealth (UNH), Humana (HUM) and Prime Therapeutics. Although the Senators were not supportive of the PBMs, the executives responded well to questions and put forth a solid effort to address concerns regarding their business model and incentives, Halper tells investors in a research note. Overall, he views the hearing as a net positive for PBMs "as the group was able to counter the negative sentiment with constructive responses, recognizing this story is far from over."

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.